+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer



Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer



Human Mutation 16(6): 491-501



In Ashkenazi (East European) Jews, three predominant mutations in BRCA1 (185delAG and 5382insC) and BRCA2 (6174delT) account for the majority of germline mutations in high-risk breast and/or ovarian cancer families. Among non-Ashkenazi Jews, the 185delAG, Tyr978Ter, and a handful of "private" mutations have been reported anecdotally within both genes. In this study we attempted to determine the spectrum of BRCA1 and BRCA2 mutations in high-risk Jewish individuals, non-carriers of any of the predominant Jewish mutations. We employed multiplex PCR and denaturing gradient gel electrophoresis (DGGE) analysis for BRCA2, and combined denaturing high performance liquid chromatography (DHPLC) and protein truncation test (PTT) for BRCA1, complemented by DNA sequencing. We screened 47 high-risk Jewish individuals, 26 Ashkenazis, and 21 non-Ashkenazis. Overall, 13 sequence alterations in BRCA1 and eight in BRCA2 were detected: nine neutral polymorphisms and 12 missense mutations, including five novel ones. The novel missense mutations did not co-segregate with disease in BRCA1 and were detected at rates of 6.25% to 52.5% in the general population for BRCA2. Our findings suggest that except for the predominant mutations in BRCA1 and BRCA2 in Jewish individuals, there are only a handful of pathogenic mutations within these genes. It may imply novel genes may underlie inherited susceptibility to breast/ovarian cancer in Jewish individuals.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011029577

Download citation: RISBibTeXText

PMID: 11102978

DOI: 10.1002/1098-1004(200012)16:6<491::aid-humu6>3.0.co;2-j


Related references

Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer. Journal of Medical Genetics 36(5): 369-373, 1999

Prevalence of specific germline mutations in BRCA1 and BRCA2 in women affected with breast or ovarian cancer from the Ashkenazi Jewish population. Journal of Medical Genetics 34(SUPPL 1): S32, 1997

BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and ovarian cancer. Genetic Testing 1(1): 41-46, 1997

BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. American Journal of Human Genetics 66(4): 1259-1272, 2000

Mutational analysis of BRCA1 and BRCA2 genes in low medium and high risk Canadian Jewish Ashkenazi ovarian cancer families. Proceedings of the American Association for Cancer Research Annual Meeting 38(0): 188, 1997

BRCA1/BRCA2 mutations and breast cancer in Ashkenazi Jewish women. Annals of the New York Academy of Sciences 833: 198-203, 1998

Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer. American Journal of Obstetrics and Gynecology 196(4): E6-E9, 2007

The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer. American Journal of Human Genetics 65(3): 921-924, 1999

Testing Ashkenazi Jewish Women for Mutations Predisposing to Breast Cancer in Genes Other Than BRCA1 and BRCA2. JAMA Oncology 4(7): 1012, 2018

Frequent occurrence of specific germline mutations of BRCA1 and BRCA2 in Ashkenazi Jewish women with breast cancer. American Journal of Human Genetics 59(4 SUPPL ): A76, 1996

An evaluation of BRCA1 and BRCA2 founder mutations penetrance estimates for breast cancer among Ashkenazi Jewish women. Genetics in Medicine 7(1): 34-39, 2005

An evaluation of Brca1 and Brca2 founder mutations penetrance estimates for breast cancer among Ashkenazi Jewish women. Genetics in Medicine 7(1): 34-39, 2005

Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. Journal of the National Cancer Institute 91(14): 1241-1247, July 21, 1999

Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women. JAMA Oncology 3(12): 1647-1653, 2017

Analysis of BRCA1/BRCA2 genes' contribution to breast cancer susceptibility in high risk Jewish Ashkenazi women. Familial Cancer 8(2): 127-133, 2008